Clinical Trial Update: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of metastatic castration-resistant prostate cancer; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 64Cu-SAR-BBN
• 67Cu-SAR-BBN

Snippet

Sponsor: Clarity Pharmaceuticals Ltd | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 1, Phase 2 | Status: TERMINATED